CHEST guidelines on biologic management in severe adult asthma offers recommendations on choosing and switching among biologic therapies.

On November 17, 2025 Formycon AG (“Formycon”) announced development of a dupilumab biosimilar, FYB208, referencing Regeneron and Sanofi’s ...

A recent study has found that dupilumab significantly decreased the mucus plug score and improved lung function in patients ...

A meta-analysis shows varying effectiveness of treatments in restoring smell in patients with chronic rhinosinusitis with ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

European Commission approves Sanofi & Regeneron’s Dupixent to treat moderate-to-severe chronic spontaneous urticaria: Paris Wednesday, November 26, 2025, 14:00 Hrs [IST] The Eur ...

Denmark: A new systematic review and meta-analysis has shed light on how effectively biologic therapies can help restore the ...

EoE diagnosis is on the rise, and not all treatments have been successful. A Utah physician researcher explores how diet and ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...